PPI‐amoxicillin dual therapy for Helicobacter pylori infection: An update based on a systematic review and meta‐analysis
Sign Up to like & getrecommendations! Published in 2020 at "Helicobacter"
DOI: 10.1111/hel.12692
Abstract: The efficacy of PPI‐amoxicillin dual therapy (high‐dose dual therapy) in the eradication of Helicobacter pylori is controversial. We aimed to investigate whether PPI‐amoxicillin dual therapy is effective. read more here.
Keywords: amoxicillin dual; dual therapy; ppi amoxicillin; therapy ... See more keywords
Optimization of vonoprazan‐amoxicillin dual therapy for eradicating Helicobacter pyloriinfection in China: A prospective, randomized clinical pilot study
Sign Up to like & getrecommendations! Published in 2022 at "Helicobacter"
DOI: 10.1111/hel.12896
Abstract: Vonoprazan‐amoxicillin (VA) dual therapy has been shown to achieve acceptable cure rates for treatment of Helicobacter pylori(H. pylori) in Japan. Its effectiveness in other regions is unknown. We aimed to explore the efficacy of VA… read more here.
Keywords: therapy; dual therapy; vonoprazan amoxicillin; amoxicillin dual ... See more keywords
Fourteen-day vonoprazan and low- or high-dose amoxicillin dual therapy for eradicating Helicobacter pylori infection: A prospective, open-labeled, randomized non-inferiority clinical study
Sign Up to like & getrecommendations! Published in 2023 at "Frontiers in Immunology"
DOI: 10.3389/fimmu.2022.1049908
Abstract: Background and aim We previously reported that vonoprazan-amoxicillin (VA) dual therapy for 7 or 10 days is not satisfactorily efficacious for Helicobacter pylori (H. pylori) eradication. We aimed to explore the efficacy of VA dual… read more here.
Keywords: amoxicillin dual; pylori infection; dose; dual therapy ... See more keywords